# LinkedIn Post — Project 2: RAI Maturity Assessment, NovaSynth Biologics

---

## POST DRAFT (Long-form — recommended for maximum reach)

---

🧬 **When Gen AI meets drug discovery — and nobody built the governance framework first.**

This is the second project in my Responsible AI governance portfolio. It's the one that keeps me up at night.

Here's the scenario:

**NovaSynth Biologics** deployed **SynthMind** — a Gen AI platform (LLM + RAG) — to accelerate molecule screening and clinical trial patient matching. Six months in, an internal audit raises concerns ahead of an EMA inspection. I'm brought in to assess.

What I found: **Overall RAI maturity: Level 1 out of 5. Two domains at Level 0.**

Not level 2. Not "developing." Level 0 — *non-existent.*

---

**The four Critical risks that stopped me in my tracks:**

🔴 **No governance framework.** The platform was approved informally by the CSO. No accountability owner. No committee. No policy. No AI system inventory.

🔴 **Patient matching without a validation protocol.** Clinical trial coordinators were receiving AI recommendations and acting on them. No structured human review. No sign-off. No audit trail. For a system selecting patients for medical trials.

🔴 **Zero explainability.** SynthMind outputs are fluent, confident LLM narratives — with no source citations, no retrieval trace, no confidence score. Researchers had no way to verify *how* a recommendation was reached.

🔴 **Unaudited training and retrieval data.** The RAG knowledge base was populated with unpublished internal research, licensed databases, and scraped literature. IP status? Undocumented. Consent review? Never done.

---

**Why this matters beyond one fictional company:**

Gen AI adoption in pharma and life sciences is accelerating. The pressure to move fast is immense — competitive advantage, drug development timelines, investor expectations.

But when your AI is touching:
- Molecule screening that directs R&D investment
- Patient selection for clinical trials
- Data governed by GCP, FDA SaMD, EU AI Act, and GDPR

...the cost of moving fast without governance is not a compliance fine. It's patient safety. It's regulatory enforcement that halts your clinical programme. It's IP loss you can't recover.

---

**What good governance looks like here:**

The maturity assessment I conducted covers 7 domains against a 0–5 scale, with a 12-month roadmap to move from Level 1 to Level 3 (Defined). The key moves:

✅ Appoint an AI Accountability Owner and establish a governance committee — within 30 days
✅ Suspend autonomous use of patient matching — implement mandatory PI sign-off for every output
✅ Implement RAG source citations and an output audit log — every recommendation must be traceable
✅ Conduct a full data provenance audit of the knowledge base
✅ Commission EU AI Act conformity assessment and FDA SaMD classification review
✅ Build the monitoring, change control, and incident response infrastructure that should have been there on day one

---

**What I built for this project:**

📋 Full RAI Maturity Assessment — 7 domains, gap analysis, 12-month roadmap
⚠️ Risk Register — 14 risks scored across data, model, operational, ethical, and regulatory dimensions
📜 AI Governance Policy — accountability structure, RACI, permitted/prohibited uses, human review protocol, incident response
🗺️ Regulatory Alignment — EU AI Act · FDA SaMD · ICH E6 (R3) GCP · ISO 42001:2023 · NIST AI RMF

All files are on GitHub — link in the comments.

---

If you're working on AI governance in a regulated industry, I'd love to connect. This space is evolving fast, and the frameworks we build now will define how safely this technology gets deployed.

---

*#ResponsibleAI #AIGovernance #IAPP #AIGP #GenerativeAI #Pharma #LifeSciences #EUAIAct #FDASaMD #GCP #NistAIRMF #AIRisk #MLOps #ClinicalTrials*

---

## SHORTER VERSION (for lower-effort posting)

---

🧬 Project 2 of my RAI governance portfolio is live.

Scenario: A pharma company deploys a Gen AI platform (LLM + RAG) for molecule screening and clinical trial patient matching — with no governance framework, no explainability, and no human review protocol.

Overall maturity: **Level 1 out of 5. Two domains at Level 0.**

The most concerning finding: clinical trial coordinators were using patient matching outputs with no structured validation, no audit trail, and no PI sign-off. For a system that determines which patients enter medical trials.

I built the full governance framework:
- RAI maturity assessment across 7 domains
- 14-risk register (4 Critical)
- AI governance policy with RACI and human review protocol
- 12-month roadmap to reach Level 3 maturity
- Regulatory alignment: EU AI Act · FDA SaMD · ICH E6 · ISO 42001:2023 · NIST AI RMF

Full project on GitHub — link in comments.

If you're navigating AI governance in pharma or life sciences, let's connect.

*#ResponsibleAI #AIGovernance #IAPP #AIGP #EUAIAct #FDASaMD #Pharma #LifeSciences*
